SASLT practice guidelines: management of hepatitis C virus infection.
作者信息
Alghamdi Abdullah S, Sanai Faisal M, Ismail Mona, Alghamdi Hamdan, Alswat Khalid, Alqutub Adel, Altraif Ibrahim, Shah Hemant, Alfaleh Faleh Z
机构信息
Department of Medicine, Gastroenterology Unit, King Fahad General Hospital, Jeddah, Saudi Arabia.
出版信息
Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155.
Abstract
摘要
相似文献
1
SASLT practice guidelines: management of hepatitis C virus infection.SASLT实践指南：丙型肝炎病毒感染的管理
Saudi J Gastroenterol. 2012 Sep;18 Suppl(Suppl 1):S1-32. doi: 10.4103/1319-3767.101155.
2
[Therapy of chronic hepatitis C].[慢性丙型肝炎的治疗]
Praxis (Bern 1994). 2014 Apr 9;103(8):423-36. doi: 10.1024/1661-8157/a001618.
3
4
Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.丙型肝炎病毒（HCV）感染成功抗病毒治疗13年后肝细胞癌的发生情况。
J Gastrointestin Liver Dis. 2016 Sep;25(3):408-9. doi: 10.15403/jgld.2014.1121.253.hcv.
5
Consensus guidelines for the management of hepatitis C infection.丙型肝炎感染管理的共识指南。
Saudi Med J. 2003 Jul;24 Suppl 2:S99-118.
6
Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.与聚乙二醇化干扰素-α 2b和利巴韦林相关的丙型肝炎所致紧张症
Psychosomatics. 2012 Jul-Aug;53(4):400-1. doi: 10.1016/j.psym.2012.02.007.
7
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.聚乙二醇化干扰素和利巴韦林应答导向疗法对维持性透析的慢性丙型肝炎病毒感染患者的安全性和有效性
Nephrology (Carlton). 2017 Sep;22(9):706-711. doi: 10.1111/nep.12833.
8
Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.患者摘要。聚乙二醇化干扰素联合或不联合利巴韦林用于接受血液透析的丙型肝炎患者。
Ann Intern Med. 2013 Dec 3;159(11):I-14. doi: 10.7326/0003-4819-159-11-201312030-00001.
9
"Hepatitis C (HCV) treatment is not a "one size fits all".丙型肝炎（HCV）治疗并非“一刀切”。
W V Med J. 2012 Mar-Apr;108(2):20, 22-4.
10
Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.聚乙二醇干扰素和利巴韦林治疗的慢性丙型肝炎患者病毒学应答的影响因素
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1;38(1):25-33. doi: 10.1515/prilozi-2017-0003.
引用本文的文献
1
The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021.直接作用抗病毒药物治疗沙特阿拉伯丙型肝炎病毒的有效性和安全性：一项基于沙特卫生部2017年至2021年监测数据的全国性研究。
Cureus. 2023 Aug 1;15(8):e42780. doi: 10.7759/cureus.42780. eCollection 2023 Aug.
2
Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review).血液透析患者丙型肝炎病毒感染：血液透析中心内诊断与预防规则概述（综述）
Exp Ther Med. 2020 Jul;20(1):109-116. doi: 10.3892/etm.2020.8606. Epub 2020 Mar 17.
3
Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection.从丙型肝炎病毒3型感染的有反应和无反应患者中分离出的丙型肝炎病毒RNA内部核糖体进入位点区域核苷酸序列变异的频率。
Virusdisease. 2016 Sep;27(3):251-259. doi: 10.1007/s13337-016-0335-7. Epub 2016 Aug 6.
4
Adherence and treatment satisfaction in liver transplant recipients.肝移植受者的依从性和治疗满意度。
Saudi J Gastroenterol. 2016 Mar-Apr;22(2):127-32. doi: 10.4103/1319-3767.164209.
5
Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?沙特阿拉伯病毒性肝炎的流行病学：我们是否摆脱困境了？
Saudi J Gastroenterol. 2012 Nov-Dec;18(6):349-57. doi: 10.4103/1319-3767.103425.
本文引用的文献
1
Detection of hepatitis C virus core antigen in blood donors using a new enzyme immunoassay.使用新型酶免疫测定法检测献血者中的丙型肝炎病毒核心抗原
J Family Community Med. 2004 Sep;11(3):103-7.
2
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.依西酞普兰预防无既往精神病史的丙型肝炎病毒感染患者使用聚乙二醇干扰素-α2a 相关抑郁：一项随机试验。
Ann Intern Med. 2012 Jul 17;157(2):94-103. doi: 10.7326/0003-4819-157-2-201207170-00006.
3
Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.肾移植受者丙型肝炎病毒感染治疗的疗效和安全性。
World J Gastroenterol. 2012 Jan 7;18(1):55-63. doi: 10.3748/wjg.v18.i1.55.
4
Hepatitis C virus treatment pre- and post-liver transplantation.肝移植前后丙型肝炎病毒的治疗。
Liver Int. 2012 Feb;32 Suppl 1:120-8. doi: 10.1111/j.1478-3231.2011.02714.x.
5
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.聚乙二醇干扰素α联合利巴韦林治疗慢性丙型肝炎的疗效及安全性
Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.
6
Response-guided telaprevir combination treatment for hepatitis C virus infection.基于应答指导的替拉瑞韦联合治疗丙型肝炎病毒感染。
N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463.
7
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C.丙氨酸氨基转移酶-血小板比率指数、福尔恩斯指数和FIB-4在预测慢性丙型肝炎患者显著肝纤维化和肝硬化中的应用
Turk J Gastroenterol. 2011 Jun;22(3):279-85. doi: 10.4318/tjg.2011.0213.
8
Updated thresholds for alanine aminotransferase do not exclude significant histological disease in chronic hepatitis C.更新的丙氨酸氨基转移酶界值不能排除慢性丙型肝炎的显著组织学疾病。
Liver Int. 2011 Aug;31(7):1039-46. doi: 10.1111/j.1478-3231.2011.02551.x. Epub 2011 May 31.
9
Telaprevir for previously untreated chronic hepatitis C virus infection.替拉瑞韦治疗初治慢性丙型肝炎病毒感染。
N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.
10
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.亚洲、澳大利亚和埃及丙型肝炎病毒流行病学的系统评价。
Liver Int. 2011 Jul;31 Suppl 2:61-80. doi: 10.1111/j.1478-3231.2011.02540.x.
Zotero 插件